MetaTOC stay on top of your field, easily

Association of serum osteocalcin levels with major adverse cardiovascular events: a 4.4‐year retrospective cohort study

, , , , , , ,

Clinical and Experimental Pharmacology and Physiology

Published online on

Abstract

We investigated whether the serum osteocalcin levels at baseline were associated with the incidence of major adverse cardiovascular events (MACE) in a population‐based retrospective cohort study of Chinese subjects. Coronary angiography was used to diagnose coronary artery disease (CAD). Survival curves were analyzed by performing log‐rank tests with Kaplan‐Meier figures. Multivariable Cox proportional hazards regression was performed to identify the association of serum osteocalcin levels with the incidence of MACE. A total of 247 subjects with a mean age of 65.50 ± 10.38 years were enrolled in the analysis. After a mean follow‐up time of 4.4 ± 2.6 years, MACE occurred in 175 cases. For men patients, those with serum osteocalcin levels higher than 17.22 ng/mL had significantly lower fasting plasma glucose (FPG) than those with serum osteocalcin levels lower than 17.22 ng/mL (P < 0.05). According to the multivariate Cox proportional hazards regression, the lower serum osteocalcin levels and the higher risk of future MACE occurred in men with CAD at baseline (Hazard ratio = 0.970; 95% confidence interval 0.943–0.999, P = 0.04). However, this difference was not significant in either men without CAD or in women. In conclusion, relatively lower serum osteocalcin levels were associated with a higher risk of MACE in Chinese men with CAD. This article is protected by copyright. All rights reserved.